Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative...
Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not...
View ArticleUTHealth scientists identify inhibitory switch to prevent peripheral vascular...
Millions of people in the United States have a circulatory problem of the legs called peripheral vascular disease. It can be painful and may even require surgery in serious cases. This disease can lead...
View ArticleFDA approves EYLEA Injection for treatment of Diabetic Macular Edema
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME).
View ArticleNew molecular test kit predicts survival outcomes in kidney cancer patients
Researchers and doctors at the Institute of Bioengineering and Nanotechnology (IBN), Singapore General Hospital (SGH) and National Cancer Centre Singapore (NCCS) have co-developed the first molecular...
View ArticleEuropean Commission approves EYLEA Injection for treatment of visual...
Regeneron Pharmaceuticals, Inc. today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema.
View ArticleOncoSynergy's OS2966 receives FDA orphan drug designation for treatment of...
OncoSynergy announced today that the FDA Office of Orphan Products Development has granted orphan drug designation for the investigational drug candidate OS2966, a neutralizing anti-CD29 monoclonal...
View ArticleStudy: Brain tumors hijack the brain's existing blood supply during progression
Dangerous brain tumors hijack the brain's existing blood supply throughout their progression, by growing only within narrow potential spaces between and along the brain's thousands of small blood...
View ArticleExperts open new clinic to evaluate heart disease patients for participation...
Regenerative medicine experts at the Cedars-Sinai Heart Institute have opened a new clinic to evaluate heart and vascular disease patients for participation in stem cell medical studies.
View ArticleColorectal cancer therapies market to remain constant at $7.7 billion by 2023
Decision Resources Group finds that the market for colorectal cancer (CRC) therapies will remain constant, at around $7.7 billion by 2023 in the United States, France, Germany, Italy, Spain, the United...
View ArticleKIT spinoff amcure develops tumor therapeutic agents to reduce mortality rate
There is an urgent need for medical agents to treat metastatic tumors. In case of pancreatic cancer, one of the most aggressive types of cancer that is often detected late, 95% of the patients die...
View ArticleTransplantation of B10 cells helps inhibit development of bladder fibrosis...
A team of researchers from Korea and Canada have found that transplantation of B10 cells (a stable immortalized human bone marrow derived -mesenchymal stem cell line; B10 hMSC) directly into the...
View ArticleProfessor receives award for development of anti-angiogenic therapy for...
Napoleone Ferrara, MD, distinguished professor of pathology and distinguished adjunct professor of ophthalmology at the University of California, San Diego School of Medicine and senior deputy director...
View ArticleRamucirumab Phase III study meets primary endpoint in patients with...
Eli Lilly and Company today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its...
View ArticleSpecific blood test could indicate neoadjuvant treatment regimens for ESCC...
A blood test may be beneficial in indicating neoadjuvant treatment regimens for patients with esophageal squamous cell carcinoma (ESCC), according to research presented today at the American Society...
View ArticleFDA grants Breakthrough Therapy designation to EYLEA Injection for treatment...
Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has granted EYLEA (aflibercept) Injection Breakthrough Therapy designation for the treatment of diabetic...
View ArticleSurvival benefits with erlotinib plus bevacizumab in EGFR-Mutated NSCLC
Combining erlotinib with bevacizumab could prolong progression-free survival in patients being treated for epidermal growth factor receptor-mutated non-small-cell lung cancer, phase II trial results...
View ArticleEYLEA Injection gets approval in Japan for treatment of myopic CNV
Regeneron Pharmaceuticals, Inc. today announced that Bayer HealthCare's Japanese subsidiary, Bayer Yakuhin, Ltd. has received approval from the Japanese Ministry of Health, Labour and Welfare for EYLEA...
View ArticlePhotoacoustics could become alternative to mammography or sonogram for breast...
One of the lines of research of OILTEBIA, a European science project coordinated by Universidad Carlos III de Madrid, is a method to detect breast cancer based on photoacoustics and which could become...
View ArticleNCCN ORP awards four research grants to advance development of nintedanib
The National Comprehensive Cancer Network Oncology Research Program has awarded four grants to investigators to evaluate and define the clinical effectiveness of the investigational compound nintedanib...
View ArticleFDA approves CYRAMZA in combination with paclitaxel for advanced adenocarcinoma
Eli Lilly and Company announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA (ramucirumab) in combination with paclitaxel (a type of chemotherapy) as a treatment for...
View Article
